Last reviewed · How we verify

NCT06573450

Exhaled Breath Condensate Biomarkers in CARAS

Recruiting now Last updated 28 August 2024
What this trial tests

trial testing questionnaire survey in Combined Allergic Rhinitis and Asthma Syndrome in 270 participants. Currently enrolling.

Timeline
1 April 2023
Primary endpoint
30 May 2025
30 May 2025

Quick facts

Lead sponsorHenan University of Traditional Chinese Medicine
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment270
Start date1 April 2023
Primary completion30 May 2025
Estimated completion30 May 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Henan University of Traditional Chinese Medicine

Who can join

Adults 18 to 80, any sex, with Combined Allergic Rhinitis and Asthma Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To explore the differences in the expression of biomarkers in different sample types between the healthy population and different subgroups of the disease, and to screen for potential biomarkers in a more simple, direct and objective way. To screen the biomarkers that can be identified by CARAS Chinese medicine symptoms and different stages, and to provide a reference basis for individualised diagnosis and treatment of the disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of questionnaire survey

Trials testing the same drug.

Other Henan University of Traditional Chinese Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06573450.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing